Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium.

Autor: Stefanski HE; Division of Pediatric Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN., Eaton A; Division of Biostatistics, University of Minnesota School of Public Health, Minneapolis, MN., Baggott C; Division of Hematology/Oncology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA., Rossoff J; Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL., Verneris MR; Center for Cancer and Blood Disorders, Children's Hospital of Colorado, University of Colorado School of Medicine, Aurora, CO., Prabhu S; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA., Pacenta HL; Department of Pediatrics, University of Texas Southwestern Medical Center/Children's Health, Dallas, TX.; Division of Hematology and Oncology, Cook Children's Medical Center, Fort Worth, TX., Phillips CL; Department of Pediatrics, University of Cincinnati, Cincinnati, OH.; Cancer and Blood Disease Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH., Talano JA; Division of Hematology/Oncology/Blood and Marrow Transplantation, Department of Pediatrics, Medical College of Wisconsin and Children's Wisconsin, Milwaukee, WI., Moskop A; Division of Hematology/Oncology/Blood and Marrow Transplantation, Department of Pediatrics, Medical College of Wisconsin and Children's Wisconsin, Milwaukee, WI., Margossian SP; Pediatric Hematology-Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA., Myers GD; Division of Hematology and Oncology, Children's Mercy Hospital, University of Missouri Kansas City, Kansas City, MO., Karras NA; Department of Pediatrics, City of Hope National Medical Center, Duarte, CA., Brown PA; Department of Oncology, Sidney Kimmel Cancer Center, John Hopkins School of Medicine, Baltimore, MD., Qayed M; Winship Cancer Institute, Emory University and Children's Healthcare of Atlanta, Atlanta, GA., Hermiston M; Pediatric Hematology/Oncology, Department of Pediatrics, Benioff Children's Hospital, University of California San Francisco, San Francisco, CA., Satwani P; Division of Pediatric Hematology, Oncology and Stem Cell Transplant, Department of Pediatrics, Columbia University Irving Medical Center, New York, NY., Krupski MC; Department of Pediatrics, University of Cincinnati, Cincinnati, OH.; Cancer and Blood Disease Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH., Keating AK; Center for Cancer and Blood Disorders, Children's Hospital of Colorado, University of Colorado School of Medicine, Aurora, CO., Wilcox R; Division of Hematology and Oncology, Children's Mercy Hospital, University of Missouri Kansas City, Kansas City, MO., Rabik CA; Division of Hematologic Malignancies I, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD., Fabrizio VA; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Pediatrics, Weill Cornell Medical College, New York, NY., Chinnabhandar V; Division of Pediatric Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN., Goksenin AY; Pediatric Hematology/Oncology, Department of Pediatrics, Benioff Children's Hospital, University of California San Francisco, San Francisco, CA., Curran KJ; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Pediatrics, Weill Cornell Medical College, New York, NY., Mackall CL; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA.; Division of Hematology and Oncology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA.; Division of Blood and Bone Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, Stanford, CA., Laetsch TW; Department of Pediatrics, University of Texas Southwestern Medical Center/Children's Health, Dallas, TX.; Department of Pediatrics, University of Pennsylvania, Philadelphia, PA.; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.; Division of Oncology, Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA., Schultz LM; Division of Hematology/Oncology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA.

Publikováno v: Blood advances [Blood Adv] 2023 Feb 28; Vol. 7 (4), pp. 541-548.

Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy.

Autor: Fabrizio VA; Colorado Children's Hospital, Anschutz Medical Campus, University of Colorado, Aurora, CO., Boelens JJ; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Pediatrics, Weill Cornell Medical College, New York, NY., Mauguen A; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY., Baggott C; Division of Hematology and Oncology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA., Prabhu S; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA., Egeler E; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA., Mavroukakis S; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA., Pacenta H; Department of Pediatrics, University of Texas Southwestern Medical Center/Children's Health, Dallas, TX.; Division of Hematology and Oncology, Cook Children's Medical Center, Fort Worth, TX., Phillips CL; Department of Pediatrics, University of Cincinnati, Cincinnati, OH.; Cancer and Blood Disease Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH., Rossoff J; Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL., Stefanski HE; Division of Pediatric Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN., Talano JA; Department of Pediatric Hematology Oncology, Medical College of Wisconsin, Wauwatosa, WI., Moskop A; Department of Pediatric Hematology Oncology, Medical College of Wisconsin, Wauwatosa, WI., Margossian SP; Pediatric Hematology-Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA., Verneris MR; Colorado Children's Hospital, Anschutz Medical Campus, University of Colorado, Aurora, CO., Myers GD; Children's Mercy Hospital, Kansas City, MO., Karras NA; Department of Pediatrics, City of Hope National Medical Center, Duarte, CA., Brown PA; Department of Oncology, Sidney Kimmel Cancer Center, John Hopkins School of Medicine, Baltimore, MD., Qayed M; Children's Healthcare of Atlanta, Emory University, Atlanta, GA., Hermiston M; Benioff Children's Hospital, University of California San Francisco, San Francisco, CA., Satwani P; Division of Pediatric Hematology, Oncology and Stem Cell Transplant, Department of Pediatrics, Columbia University Medical Center, New York, NY., Krupski C; Department of Pediatrics, University of Cincinnati, Cincinnati, OH., Keating AK; Colorado Children's Hospital, Anschutz Medical Campus, University of Colorado, Aurora, CO., Wilcox R; Children's Mercy Hospital, Kansas City, MO., Rabik CA; Department of Oncology, Sidney Kimmel Cancer Center, John Hopkins School of Medicine, Baltimore, MD., Chinnabhandar V; Division of Pediatric Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN., Kunicki M; Division of Hematology and Oncology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA., Goksenin AY; Benioff Children's Hospital, University of California San Francisco, San Francisco, CA., Mackall CL; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA.; Division of Stem Cell Transplantation and Cell Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA., Laetsch TW; Department of Pediatrics, University of Texas Southwestern Medical Center/Children's Health, Dallas, TX.; Department of Pediatrics and Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; and.; Division of Oncology, Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA., Schultz LM; Division of Hematology and Oncology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA., Curran KJ; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Pediatrics, Weill Cornell Medical College, New York, NY.

Publikováno v: Blood advances [Blood Adv] 2022 Apr 12; Vol. 6 (7), pp. 1961-1968.

Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report.

Autor: Fabrizio VA; University of Colorado, Anschutz Medical Campus, Colorado Children's Hospital, Aurora, CO., Phillips CL; Department of Pediatrics, University of Cincinnati, Cincinnati, OH.; Cincinnati Children's Hospital Medical Center, Cancer and Blood Diseases Institute, Cincinnati, OH., Lane A; Department of Pediatrics, University of Cincinnati, Cincinnati, OH., Baggott C; Division of Hematology and Oncology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA., Prabhu S; Stanford University School of Medicine, Stanford Cancer Institute, Center for Cancer Cell Therapy, Stanford, CA., Egeler E; Stanford University School of Medicine, Stanford Cancer Institute, Center for Cancer Cell Therapy, Stanford, CA., Mavroukakis S; Stanford University School of Medicine, Stanford Cancer Institute, Center for Cancer Cell Therapy, Stanford, CA., Pacenta H; Department of Pediatrics, The University of Texas Southwestern Medical Center/Children's Health, Dallas, TX., Rossoff J; Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL., Stefanski HE; Department of Pediatrics, Division of Pediatric Blood and Marrow Transplantation, University of Minnesota Medical School, Minneapolis, MN., Talano JA; Department of Pediatric Hematology Oncology, Medical College of Wisconsin, Milwaukee, WI., Moskop A; Department of Pediatric Hematology Oncology, Medical College of Wisconsin, Milwaukee, WI., Margossian SP; Harvard Medical School, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Pediatric Hematology-Oncology, Boston, MA., Verneris MR; University of Colorado, Anschutz Medical Campus, Colorado Children's Hospital, Aurora, CO., Myers GD; Children's Mercy Hospital, Kansas City, MO., Karras NA; Department of Pediatrics, City of Hope National Medical Center, Duarte, CA., Brown PA; Department of Oncology, Sidney Kimmel Cancer Center at John Hopkins School of Medicine, Baltimore, MD., Qayed M; Emory University and Children's Healthcare of Atlanta, Atlanta, GA., Hermiston M; Benioff Children's Hospital, University of California San Francisco, San Francisco, CA., Satwani P; Division of Pediatric Hematology, Oncology and Stem Cell Transplant, Department of Pediatrics, Columbia University Medical Center, New York, NY., Krupski C; Department of Pediatrics, University of Cincinnati, Cincinnati, OH.; Cincinnati Children's Hospital Medical Center, Cancer and Blood Diseases Institute, Cincinnati, OH., Keating AK; University of Colorado, Anschutz Medical Campus, Colorado Children's Hospital, Aurora, CO., Wilcox R; Children's Mercy Hospital, Kansas City, MO., Rabik CA; Department of Oncology, Sidney Kimmel Cancer Center at John Hopkins School of Medicine, Baltimore, MD., Chinnabhandar V; Department of Pediatrics, Division of Pediatric Blood and Marrow Transplantation, University of Minnesota Medical School, Minneapolis, MN., Kunicki M; Division of Hematology and Oncology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA., Goksenin AY; Benioff Children's Hospital, University of California San Francisco, San Francisco, CA., Curran KJ; Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY.; Department of Pediatrics, Weill Cornell Medical College, New York, NY., Mackall CL; Division of Hematology and Oncology, Department of Pediatrics, Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford, CA.; Division of Stem Cell Transplantation and Cell Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA., Laetsch TW; Department of Pediatrics, The University of Texas Southwestern Medical Center/Children's Health, Dallas, TX.; Department of Pediatrics and Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.; Division of Oncology, Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA; and., Schultz LM; Department of Pediatrics, Division of Hematology and Oncology, Stanford University School of Medicine, Stanford, CA.

Publikováno v: Blood advances [Blood Adv] 2022 Jan 25; Vol. 6 (2), pp. 600-610.

Explosive mutation accumulation triggered by heterozygous human Pol ε proofreading-deficiency is driven by suppression of mismatch repair.

Autor: Hodel KP; Department of Biochemistry and Molecular Biology, Tulane University School of Medicine, New Orleans, United States., de Borja R; Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Canada., Henninger EE; Department of Biochemistry and Molecular Biology, Tulane University School of Medicine, New Orleans, United States., Campbell BB; The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Canada.; Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, Canada., Ungerleider N; Department of Pathology, Tulane University School of Medicine, New Orleans, United States., Light N; Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Canada., Wu T; Department of Pathology, Tulane University School of Medicine, New Orleans, United States., LeCompte KG; Department of Biochemistry and Molecular Biology, Tulane University School of Medicine, New Orleans, United States., Goksenin AY; Department of Biochemistry and Molecular Biology, Tulane University School of Medicine, New Orleans, United States., Bunnell BA; Department of Pharmacology, Tulane University School of Medicine, New Orleans, United States.; Tulane Center for Stem Cell Research and Regenerative Medicine, Tulane University School of Medicine, New Orleans, United States., Tabori U; Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Canada.; The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Canada.; Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, Canada., Shlien A; Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Canada.; Department of Paediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, Canada.; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada., Pursell ZF; Department of Biochemistry and Molecular Biology, Tulane University School of Medicine, New Orleans, United States.; Tulane Cancer Center, Tulane University School of Medicine, New Orleans, United States.

Publikováno v: ELife [Elife] 2018 Feb 28; Vol. 7. Date of Electronic Publication: 2018 Feb 28.